Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
2.000
+0.050 (2.56%)
At close: Aug 7, 2026, 4:00 PM EDT
2.011
+0.011 (0.56%)
Pre-market: Aug 10, 2026, 5:01 AM EDT
Evotec SE Employees
Evotec SE had 4,526 employees as of March 31, 2026. The number of employees decreased by 240 or -5.04% compared to the same quarter last year.
Employees
4,526
Change
-240
Growth
-5.04%
Revenue / Employee
$189,800
Profits / Employee
-$49,390
Market Cap
711.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 4,526 | -240 | -5.04% |
| Dec 31, 2025 | 4,467 | -273 | -5.76% |
| Sep 30, 2025 | 4,788 | -219 | -4.37% |
| Jun 30, 2025 | 4,759 | -263 | -5.24% |
| Mar 31, 2025 | 4,766 | -289 | -5.72% |
| Dec 31, 2024 | 4,740 | -321 | -6.34% |
| Sep 30, 2024 | 5,007 | -79 | -1.55% |
| Jun 30, 2024 | 5,022 | -45 | -0.89% |
| Mar 31, 2024 | 5,055 | 103 | 2.08% |
| Dec 31, 2023 | 5,061 | 109 | 2.20% |
| Sep 30, 2023 | 5,086 | 371 | 7.87% |
| Jun 30, 2023 | 5,067 | 546 | 12.08% |
| Dec 31, 2022 | 4,952 | 754 | 17.96% |
| Sep 30, 2022 | 4,715 | 634 | 15.54% |
| Jun 30, 2022 | 4,521 | 607 | 15.51% |
| Mar 31, 2022 | 4,354 | 619 | 16.57% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 3,595 |
| Amphastar Pharmaceuticals | 1,976 |
| Canopy Growth | 1,128 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Glass House Brands | 426 |
| Collegium Pharmaceutical | 423 |
| Evolus | 350 |
EVO News
- 4 days ago - Evotec enters R&D collaboration with Odyssey Therapeutics - TheFly
- 4 days ago - Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - PRNewsWire
- 6 days ago - Niagen Bioscience selects Evotec to advance development for NB4168 - TheFly
- 6 days ago - Niagen Bioscience, Inc: Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 - Finanz Nachrichten
- 6 days ago - Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 - Business Wire
- 8 days ago - Evotec SE Slides: Company presentation - Filings
- 18 days ago - Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management - Business Wire
- 24 days ago - Evotec price target lowered to EUR 3.50 from EUR 4.50 at Deutsche Bank - TheFly